Zoetis (NYSE:ZTS) Updates FY 2026 Earnings Guidance

Zoetis (NYSE:ZTS) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 7.000-7.100 for the period, compared to the consensus estimate of 6.810. The company issued revenue guidance of $9.8 billion-$10.0 billion, compared to the consensus revenue estimate of $9.7 billion.

Zoetis Trading Up 0.6%

Shares of Zoetis stock opened at $128.85 on Thursday. Zoetis has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The company has a market capitalization of $56.79 billion, a P/E ratio of 21.69, a P/E/G ratio of 2.21 and a beta of 0.96. The company has a fifty day moving average of $124.16 and a 200 day moving average of $135.79.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts anticipate that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.6%. Zoetis’s payout ratio is currently 35.69%.

Analyst Ratings Changes

ZTS has been the subject of a number of research analyst reports. Barclays initiated coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a research note on Monday, December 15th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Finally, UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $152.45.

Hedge Funds Weigh In On Zoetis

Large investors have recently modified their holdings of the stock. Bellevue Group AG increased its stake in Zoetis by 32.7% in the third quarter. Bellevue Group AG now owns 872 shares of the company’s stock worth $128,000 after purchasing an additional 215 shares during the period. Newbridge Financial Services Group Inc. boosted its stake in shares of Zoetis by 23.7% during the third quarter. Newbridge Financial Services Group Inc. now owns 1,145 shares of the company’s stock valued at $168,000 after purchasing an additional 219 shares during the period. State of Wyoming grew its holdings in shares of Zoetis by 13.9% in the fourth quarter. State of Wyoming now owns 1,463 shares of the company’s stock worth $184,000 after purchasing an additional 179 shares during the last quarter. Headlands Technologies LLC purchased a new position in Zoetis in the 2nd quarter worth about $194,000. Finally, Boothbay Fund Management LLC purchased a new position in Zoetis in the 2nd quarter worth about $202,000. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.